YSCH-01
- Generic Name
- YSCH-01
Safety and Tolerability Study of Recombinant L-IFN Adenovirus Injection in Patients With Recurrent Glioblastoma
Early Phase 1
Recruiting
- Conditions
- Recurring Glioblastoma
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Binhai Hospital of Fujian Medical University
- Target Recruit Count
- 6
- Registration Number
- NCT05914935
- Locations
- 🇨🇳
Binhai Hospital of Fujian Medical University, Fujian, Fujian, China
Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study
Early Phase 1
- Conditions
- Ovarian CarcinomaHead and Neck CancerMelanomaBreast CancerCervical CarcinomaLung CancerBladder Cancer
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Shanghai Fengxian District Central Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT05180851
- Locations
- 🇨🇳
Shanghai Fengxian District Central Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath